Cover Image
Market Research Report

Japanese Encephalitis - Pipeline Review, H2 2017

Published by Global Markets Direct Product code 227543
Published Content info 43 Pages
Immediate Delivery Available
Price
Back to Top
Japanese Encephalitis - Pipeline Review, H2 2017
Published: October 31, 2017 Content info: 43 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H2 2017, provides an overview of the Japanese Encephalitis (Infectious Disease) pipeline landscape.

Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. Treatment targets relief of symptoms like pain relievers and anticonvulsants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Japanese Encephalitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Japanese Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Japanese Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Japanese Encephalitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Japanese Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Japanese Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Japanese Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Japanese Encephalitis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Japanese Encephalitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Japanese Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC9811IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Japanese Encephalitis - Overview
    • Japanese Encephalitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Japanese Encephalitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Japanese Encephalitis - Companies Involved in Therapeutics Development
    • Adimmune Corp
    • Cadila Healthcare Ltd
    • Ennaid Therapeutics LLC
    • Fab'entech SA
    • Indian Immunologicals Ltd
    • Kineta Inc
    • Livzon Pharmaceutical Group Inc
    • Panacea Biotec Ltd
    • Theravectys SA
  • Japanese Encephalitis - Drug Profiles
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis [strains 1, 3 and 5] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Japanese Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Japanese Encephalitis - Dormant Projects
  • Japanese Encephalitis - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Japanese Encephalitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Japanese Encephalitis - Pipeline by Adimmune Corp, H2 2017
  • Japanese Encephalitis - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Japanese Encephalitis - Pipeline by Ennaid Therapeutics LLC, H2 2017
  • Japanese Encephalitis - Pipeline by Fab'entech SA, H2 2017
  • Japanese Encephalitis - Pipeline by Indian Immunologicals Ltd, H2 2017
  • Japanese Encephalitis - Pipeline by Kineta Inc, H2 2017
  • Japanese Encephalitis - Pipeline by Livzon Pharmaceutical Group Inc, H2 2017
  • Japanese Encephalitis - Pipeline by Panacea Biotec Ltd, H2 2017
  • Japanese Encephalitis - Pipeline by Theravectys SA, H2 2017
  • Japanese Encephalitis - Dormant Projects, H2 2017
  • Japanese Encephalitis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Japanese Encephalitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top